1,373 reports of this reaction
3.2% of all MIDAZOLAM reports
#3 most reported adverse reaction
SEIZURE is the #3 most commonly reported adverse reaction for MIDAZOLAM, manufactured by UCB, Inc.. There are 1,373 FDA adverse event reports linking MIDAZOLAM to SEIZURE. This represents approximately 3.2% of all 42,629 adverse event reports for this drug.
Patients taking MIDAZOLAM who experience seizure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEIZURE is moderately reported among MIDAZOLAM users, representing a notable but not dominant share of adverse events.
In addition to seizure, the following adverse reactions have been reported for MIDAZOLAM:
The following drugs have also been linked to seizure in FDA adverse event reports:
SEIZURE has been reported as an adverse event in 1,373 FDA reports for MIDAZOLAM. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEIZURE accounts for approximately 3.2% of all adverse event reports for MIDAZOLAM, making it one of the most commonly reported side effect.
If you experience seizure while taking MIDAZOLAM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.